Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Chimerix Inc chart...

About the Company

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

CEO

Michael Sherman

Exchange

NASDAQ

Website

http://www.chimerix.com/

$0M

Total Revenue

103

Employees

$101M

Market Capitalization

-1.17

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CMRX News

Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript

17d ago, source: InvestingChannel on MSN

February 29, 2024 Chimerix, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.23. CMRX isn't one ...

Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

13d ago, source:

Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 2.1%. Looking ahead, revenue ...

CMRX Apr 2024 1.000 put

2d ago, source: Yahoo Finance

Chimerix ( NASDAQ:CMRX ) Full Year 2023 Results Key Financial Results Net loss: US$82.1m (down by 148% from US$172.2m... Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript February 29, 2024 ...

Rare Stock Picks In February 2024 - From 32 Discerning Analysts

13d ago, source:

Rare Stock Picks series, we're highlighting February 2024 investment picks. Click here for the list of February 2024 Buy ...

Defense Sec. defends his secret absence

on MSN ago, source:

Defense Secretary Lloyd Austin squared off with the House lawmakers Thursday about his secret hospital stay, following complications from prostate cancer surgery.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...